NewLimit
About NewLimit
NewLimit is developing epigenetic reprogramming medications that restore youthful function in aging cells, specifically targeting the immune system and liver. By utilizing single-cell genomics and machine learning, the company aims to address diseases associated with aging and extend human healthspan.
```xml <problem> Aging cells accumulate epigenetic changes that impair their function, contributing to age-related diseases and limiting overall healthspan. The immune system and liver are particularly vulnerable to these age-related declines, impacting their ability to fight off infections and maintain metabolic homeostasis. </problem> <solution> NewLimit is developing epigenetic reprogramming therapeutics designed to restore youthful function to aging cells, with initial focus on the immune system and liver. The company leverages single-cell genomics, machine learning, and high-throughput functional assays to identify and target key epigenetic drivers of aging. By reprogramming the epigenome, NewLimit aims to reverse age-related cellular dysfunction, thereby treating diseases associated with aging and ultimately extending human healthspan. Their approach seeks to rejuvenate cells by resetting their epigenetic state to a younger, more functional profile. </solution> <features> - Single-cell genomics to map epigenetic changes associated with aging in specific cell types - Machine learning models to identify key epigenetic targets for reprogramming - High-throughput functional assays to screen and validate potential therapeutic interventions - Targeted epigenetic reprogramming of immune cells to enhance immune function in older individuals - Epigenetic rejuvenation of liver cells to improve metabolic function and reduce age-related liver diseases </features> <target_audience> The primary target audience includes individuals at risk of or affected by age-related diseases, as well as researchers and clinicians focused on aging and regenerative medicine. </target_audience> ```
What does NewLimit do?
NewLimit is developing epigenetic reprogramming medications that restore youthful function in aging cells, specifically targeting the immune system and liver. By utilizing single-cell genomics and machine learning, the company aims to address diseases associated with aging and extend human healthspan.
Where is NewLimit located?
NewLimit is based in South San Francisco, United States.
When was NewLimit founded?
NewLimit was founded in 2022.
How much funding has NewLimit raised?
NewLimit has raised 72250000.
- Location
- South San Francisco, United States
- Founded
- 2022
- Funding
- 72250000
- Employees
- 37 employees